TickerGuard
Buy Day today: Neutral (52) Mixed market breadth · no major macro event
CING

Cingulate Inc

Healthcare · Biotechnology

4.30$ -4.2% vs. previous close Closing price · As of: Nov 13, 2026

Ownership

Ownership Structure

Who owns Cingulate Inc (CING)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 97.7% of the shares are freely tradable; institutional investors hold 10.5%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 10.5%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 30.5%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 97.7%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 10.0%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 15Mio.

Largest Shareholders

Institutions

Institutions CING
Name Stake (%) Shares Change (%) Date
Vanguard Capital Management, LLC 3.93 570,873 +84.8 06/30/2026
Chicago Partners Investment Group LLC 1.30 188,429 +905.0 06/30/2026
Kestra Advisory Services, LLC 1.04 151,500 +8.2 06/30/2026
Geode Capital Management, LLC 0.99 144,636 +42.7 06/30/2026
Renaissance Technologies Corp 0.88 127,500 +299.8 06/30/2026
Vanguard Fiduciary Trust Co 0.54 79,160 +58.1 06/30/2026
BlackRock Inc 0.37 53,130 +128.3 06/30/2026
BCV Asset Management Inc. 0.35 51,200 +0.0 06/30/2026

Funds

Funds CING
Name Stake (%) Shares Change (%) Date
Vanguard MStar Total Stk Mkt Idx Invest 2.71 394,555 +0.0 09/30/2026
Fidelity Extended Market Index 0.49 71,115 -0.4 09/30/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: November 13, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?